Abstract YO15
Case summary
Nasopharyngeal carcinoma in pregnancy: A Case Report
Background:
Nasopharyngeal carcinoma (NPC) in pregnancy presents a dilemma in managing the patient with much consideration to both mother and the unborn child.
Aims: To present the treatment outcome of nasopharyngeal carcinoma in pregnancy. Methods/design: Case report.
Results: This is a case of a 33-year old female who presented with a gradually enlarging bilateral neck masses during her second trimester of pregnancy. Her neck CT Scan showed a nasopharyngeal mass which was more prominent at the right measuring 3.3 x 5.3 x 3.0 cm. There were inhomogenously enhancing lobulated densities in the lateral cervical areas with the largest measuring 11.6 x 5.8 x 7.0 cm. Inhomogenously enhancing densities were seen in the supraclavicular, posterior and anterior cervical and submandibular areas with the largest seen at the right supraclavicular area measuring 1.8 x 2.5 x 2.1 cm. Punch biopsy of the nasopharyngeal mass revealed it to be morphologically consistent with nasopharyngeal carcinoma, non keratinizing, differentiated type (T3N3M0). Metastatic work up was unremarkable. She consented to begin her treatment with Gemcitabine and Cisplatin every 21 days as induction chemotherapy. Since the neck masses continued to rapidly increase in size after three cycles of chemotherapy, she was shifted to Paclitaxel and Carboplatin. At 26 weeks of gestation, she delivered a male infant weighing 970 grams with APGAR scores of 8 and 8 at 1 and 5 minutes, respectively, via normal vaginal spontaneous delivery with complete breech extraction. She has completed 6 cycles of chemotherapy and 70 Gy in 35 fractions of intensity modulated radiation therapy. The infant showed no anatomical and organ malformations. The patient showed an almost complete response after six cycles of chemotherapy.
Conclusion: Systemic chemotherapy in a pregnant NPC patient can be administered initially as a means of a delaying measure to reach a certain period of gestation where it is safer to deliver the baby. Radiation therapy can follow after the delivery to spare the unborn child from the hazards of radiation. Guided and shared decision making between the patient, family, and her physicians is vital in directing the management of NPC in pregnancy.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06